๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Active specific immunotherapy and immunochemotherapy in the treatment of lung and colon cancer

โœ Scribed by Ariel Hollinshead


Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
629 KB
Volume
7
Category
Article
ISSN
8756-0437

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

In this seminar, we describe 1) the immunogen TAA used for lung cancer immunotherapy and the immunogen TAA used for colon cancer immunotherapy, 2) the methods used in the administration of these immunogens in clinical trials of specific active TAA immunotherapy, 3) the results of clinical trials of specific active immunotherapy for lung cancer and for colon cancer patients, 4) the results of immune response monitoring evaluations, and what they indicate, and 5) the way in which certain drugs, selected for their action in the immune system, may be synergistic with specific active TAA immunotherapy, in combination therapy, especially for resected patients of later stages.


๐Ÿ“œ SIMILAR VOLUMES


Progress in active specific immunotherap
โœ Benjamin A. Tjoa; Gerald P. Murphy ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 124 KB ๐Ÿ‘ 2 views

Treatments available for metastatic prostate cancer have failed to demonstrate significant curative potential. Current efforts are now directed towards developments of novel strategies for the treatment of metastatic prostate cancer. Cancer immunotherapeutic strategies utilize patient immune system

Topoisomerase I and II activity in human
โœ Howard L. McLeod; Fiona Douglas; Melanie Oates; R. Paul Symonds; Drew Prakash; A ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 534 KB

The identification of human DNA topoisomerases as cellular targets for active anti-cancer drugs has stimulated further interest in topoisomerase function in tumour biology. Topoisomerase I and II catalytic activity is detectable in many normal and malignant tissues. However, little is known about th